For the quarter ending 2025-09-30, RNTX had -$1,674K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,581 | -12,323 |
| Commitment fee related to pre-paid advance agreement | 300 | - |
| Original issue discount related to pre-paid advance agreement | 100 | - |
| Depreciation and amortization expense | 0 | 1 |
| Stock-based compensation expense | 1,447 | 520 |
| Prepaid expenses and other current assets | 219 | 115 |
| Other assets | -2,344 | 2,344 |
| Accounts payable | -1,905 | 5,117 |
| Operating lease liabilities | 0 | 0 |
| Accrued expenses and other current liabilities | -34 | -3,172 |
| Other long-term liabilities | 0 | -277 |
| Net cash used in operating activities | -3,548 | -12,593 |
| Proceeds from issuance of common stock, net of offering costs | 0 | 367 |
| Proceeds from pre-paid advances | 1,900 | - |
| Proceeds from issuance of common stock in connection with stock option exercises | 0 | 1 |
| Proceeds from issuance of common stock in connection with warrant exercises | 0 | 1,595 |
| Proceeds from issuance of warrants, net of offering costs | 0 | 481 |
| Proceeds from warrant exchanges, net of offering costs | 0 | 2,984 |
| Proceeds from warrant exercises with common stock subscribed | 0 | 22 |
| Net cash provided by financing activities | 1,900 | 5,450 |
| Effect of exchange rate changes on cash and cash equivalents | -26 | 0 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -1,674 | -7,143 |
| Cash and cash equivalents at beginning of period | 12,865 | - |
| Cash and cash equivalents at end of period | 4,048 | - |
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)